Sagimet Biosciences’ (SGMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sagimet Biosciences (NASDAQ:SGMT) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $29.00 price objective on the stock. HC Wainwright also issued estimates for Sagimet Biosciences’ Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $2.28 EPS.

Several other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group increased their price objective on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen lowered Sagimet Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Barclays raised Sagimet Biosciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $8.00 to $18.00 in a research note on Wednesday, September 9th. The Goldman Sachs Group assumed coverage on Sagimet Biosciences in a report on Thursday, September 24th. They set a “sell” rating and a $7.00 target price for the company. Finally, Guggenheim raised their price target on Sagimet Biosciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

Sagimet Biosciences Trading Up 1.4%

Shares of NASDAQ:SGMT opened at $8.88 on Monday. The company has a market cap of $551.98 million, a price-to-earnings ratio of -6.94 and a beta of 3.46. The company has a 50-day moving average price of $9.92 and a 200-day moving average price of $7.86. Sagimet Biosciences has a 12 month low of $4.50 and a 12 month high of $11.45.

Sagimet Biosciences (NASDAQ:SGMT) last posted its earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). As a group, research analysts forecast that Sagimet Biosciences will post -1.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sagimet Biosciences news, insider Elizabeth Rozek sold 10,545 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $81,829.20. Following the completion of the sale, the insider directly owned 224,414 shares in the company, valued at $1,741,452.64. This trade represents a 4.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of Sagimet Biosciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total value of $201,049.70. Following the sale, the director directly owned 62,161 shares in the company, valued at approximately $618,501.95. The trade was a 24.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 113,646 shares of company stock worth $920,491 over the last three months. Company insiders own 11.50% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in Sagimet Biosciences by 82.6% during the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after buying an additional 282,969 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Sagimet Biosciences in the 2nd quarter worth about $3,119,000. Bank of New York Mellon Corp bought a new position in shares of Sagimet Biosciences in the 2nd quarter worth about $1,551,000. Dimensional Fund Advisors LP lifted its position in Sagimet Biosciences by 99.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after acquiring an additional 135,178 shares during the period. Finally, AWM Investment Company Inc. purchased a new position in Sagimet Biosciences during the 2nd quarter valued at about $618,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.27 from a loss of $0.32, suggesting a better-than-previously-expected near-term earnings outlook. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: The analyst also improved its loss estimates for FY2026, FY2027 and FY2028 to $1.31, $1.03 and $0.64 per share, respectively, from prior estimates of $1.48, $1.22 and $0.85. Smaller projected losses indicate improving profitability expectations. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: HC Wainwright continues to forecast a transition to profitability, projecting positive EPS of $0.89 in FY2029, up from $0.81 previously. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings
• Neutral Sentiment: The analyst estimates Sagimet will remain unprofitable through FY2028, while the company’s current-year consensus loss is $1.17 per share. This highlights that the investment case still depends on successful future execution and commercialization.
• Negative Sentiment: HC Wainwright slightly reduced its FY2030 EPS forecast to $2.28 from $2.34. However, the estimate remains profitable and follows its increased FY2029 forecast, limiting the negative significance. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings

About Sagimet Biosciences

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.